This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio
5 Best Biotech Bets Likely to Outperform Estimates in Q4
by Zacks Equity Research
Let us take a look at five promising biotech stocks for the fourth quarter of 2018.
Celgene (CELG) Provides Guidance for 2019, Updates Pipeline
by Zacks Equity Research
Celgene (CELG) announces guidance for 2019, and other pipeline and regulatory updates.
Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus
by Sweta Killa
The news has put the spotlight on a number of healthcare ETFs, especially biotech and pharma, which could be the best ways for investors to tap the opportunity arising from the BMY-CELG deal.
Biotech Stock Roundup: ASH Meet in Focus, Gilead's Drugs Get Approval in China
by Zacks Equity Research
This week, focus was on data presented at the annual conference of the American Society of Hematology from Dec 1-4. Apart from this, the regular pipeline updates were also in focus in the biotech sector.
Global Blood Therapeutics' Voxelotor on Faster Approval Path
by Zacks Equity Research
Global Blood Therapeutics (GBT) announces FDA nod for an accelerated approval pathway for voxelotor as a treatment for sickle cell disease. Stock rallies.
Celgene (CELG) Announces Various Cancer Data at ASH 2018
by Zacks Equity Research
Celegne (CELG) presents data from several cancer studies at the annual meeting of American Society of Hematology (ASH).
Bluebird (BLUE) Down 5.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celgene & Bluebird's CAR T Therapy Study Completes Enrollment
by Zacks Equity Research
Celgene (CELG) and partner bluebird complete enrollment in a phase II study for CAR T cell therapy candidate, bb2121 for patients with relapsed and refractory multiple myeloma.
Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News
by Zacks Equity Research
Pipeline and regulatory updates are the key highlights in the biotech sector this week.
Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Regeneron (REGN) Q3 results beat on earnings, while sales meet expectations. However, the company's dependence on Eylea to boost revenues is a concern.
bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.
Bluebird Bio (BLUE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 5.21% and 39.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Is a Disappointment in Store for bluebird (BLUE) Q3 Earnings?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when bluebird (BLUE) reports third-quarter results.
Analysts Estimate Bluebird Bio (BLUE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celgene (CELG) Tops Q3 Earnings & Sales Estimates, Ups View
by Zacks Equity Research
Celgene (CELG) third-quarter revenues gain on strong sales of Otezla and Revlimid.
Celgene's Otezla Meets Goal in Scalp Plaque Psoriasis Study
by Zacks Equity Research
Celgene's (CELG) efforts to expand psoriasis drug, Otezla gets a boost as the late-stage study for the indication of plaque psoriasis of the scalp meets primary endpoint.
Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy
by Neena Mishra
2018 Nobel Prize for medicine was awarded for immunotherapy research. Here is what investors need to know about stocks and ETF focused on this innovative area.
bluebird's MAA for LentiGlobin Gene Therapy Accepted by EMA
by Zacks Equity Research
bluebird's marketing authorization application (MAA) for its experimental gene therapy, LentiGlobin, was accepted by the regulatory body in Europe.
Upcoming Earnings to Watch: KR, PLAY, TLRD
by Ryan McQueeney
Will any of the earnings reports coming in the next few days have enough positive news to outweigh other headwinds? Let's take a closer look.
bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy
by Zacks Equity Research
bluebird bio (BLUE) announces updated results from phase II/III Starbeam study of its Lenti-D gene therapy in boys aged 17 years or below with CALD.
Software and Biotech Are Eating the World
by Kevin Cook
Technology innovation is accelerating productivity, disruption and wealth creation, but what about valuations?
Is Celgene Set to See Improved Results in the Second Half?
by Zacks Equity Research
After a series of pipeline setbacks, things are looking better for biotech bigwig Celgene (CELG) with positive data read-outs and an increase in guidance.
Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges
by Zacks Equity Research
The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.
T-Mobile-Sprint, Pepsi CEO Departs, Jamie Dimon's Latest Wisdom, & More | Free Lunch
by Ryan McQueeney
Ryan McQueeney highlights today's trending stories, including the departure of PepsiCo's CEO, Jamie Dimon's latest public wisdom, and Bluebird Bio's new partnership. Later, he recaps recent developments in the T-Mobile-Sprint merger and previews what the combined company might look like.